Home
/
KYNTRA BIO, INC.
/
Financials
/
Quarterly
KYNTRA BIO, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that KYNTRA BIO, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$31.93M
May 9, 2018
Q3
2017
Sep 30, 2017
$27.27M
Nov 8, 2017
Q2
2017
Jun 30, 2017
$29.00M
Aug 7, 2017
Q1
2018
Mar 31, 2017
$29.44M
May 9, 2018
Q3
2017
Sep 30, 2016
$30.10M
Nov 8, 2017
Q2
2017
Jun 30, 2016
$89.28M
Aug 7, 2017
Q1
2017
Mar 31, 2016
$28.28M
May 9, 2017
Q3
2016
Sep 30, 2015
$19.54M
Nov 8, 2016
Q2
2016
Jun 30, 2015
$120.55M
Aug 8, 2016
Q1
2016
Mar 31, 2015
$16.30M
May 9, 2016
Q3
2015
Sep 30, 2014
$13.66M
Nov 12, 2015
Q2
2015
Jun 30, 2014
$89.96M
Aug 13, 2015
Q1
2015
Mar 31, 2014
$17.88M
May 12, 2015
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.08M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$1.35M
Aug 11, 2025
Q1
2025
Mar 31, 2025
$2.74M
May 12, 2025
Q3
2025
Sep 30, 2024
$123.0K
Nov 10, 2025
Q2
2025
Jun 30, 2024
$998.0K
Aug 11, 2025
Q1
2025
Mar 31, 2024
$25.36M
May 12, 2025
Q3
2024
Sep 30, 2023
$40.13M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$44.32M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$36.16M
May 6, 2024
Q3
2023
Sep 30, 2022
$15.74M
Nov 6, 2023
Q2
2023
Jun 30, 2022
$29.81M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$60.83M
May 8, 2023
Q3
2022
Sep 30, 2021
$155.97M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$24.36M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$38.43M
May 9, 2022
Q3
2021
Sep 30, 2020
$44.03M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$42.89M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$24.40M
May 10, 2021
Q3
2019
Sep 30, 2019
$33.17M
Nov 5, 2020
Q2
2019
Jun 30, 2019
$191.57M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$200.64M
Nov 10, 2025
Q2
2025
Jun 30, 2025
($7.60M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
$4.64M
May 12, 2025
Q3
2025
Sep 30, 2024
($17.08M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($15.54M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($32.93M)
May 12, 2025
Q3
2024
Sep 30, 2023
($63.62M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($87.68M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($76.71M)
May 6, 2024
Q3
2023
Sep 30, 2022
($91.65M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($72.62M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($63.21M)
May 8, 2023
Q3
2022
Sep 30, 2021
$49.80M
Nov 7, 2022
Q2
2022
Jun 30, 2021
($133.99M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($71.76M)
May 9, 2022
Q3
2021
Sep 30, 2020
$33.00M
Nov 9, 2021
Q2
2021
Jun 30, 2020
($85.31M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($78.35M)
May 10, 2021
Q3
2019
Sep 30, 2019
($49.44M)
Nov 5, 2020
Q2
2019
Jun 30, 2019
$116.00M
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.41M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($12.05M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($14.92M)
May 12, 2025
Q3
2025
Sep 30, 2024
($47.69M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($46.41M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($49.18M)
May 12, 2025
Q3
2024
Sep 30, 2023
($63.48M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($88.05M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($76.09M)
May 6, 2024
Q3
2023
Sep 30, 2022
($93.66M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($78.22M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($62.99M)
May 8, 2023
Q3
2022
Sep 30, 2021
$50.97M
Nov 7, 2022
Q2
2022
Jun 30, 2021
($133.84M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($70.43M)
May 9, 2022
Q3
2021
Sep 30, 2020
$32.33M
Nov 9, 2021
Q2
2021
Jun 30, 2020
($85.14M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($81.07M)
May 10, 2021
Q3
2019
Sep 30, 2019
($52.85M)
Nov 5, 2020
Q2
2019
Jun 30, 2019
$112.82M
Aug 6, 2020